BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...
Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...
"It could be cheap, but it still could be poison." -- Stuart Weinerman, MD, of Northwell Health in Great Neck, New York, on ...
BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...
ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the ...
To be a healer is not merely to deliver care, but to create comfort. Yes, science is central, but healing encompasses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback